Key Brands and Treatment Options Meeting the Growing Demand for Anti-Infective Medicines Exploring Insights Understanding the Importance of Anti-Infective Medicines in Modern Healthcare Most In-Demand Anti-Infective Brands of 2023 MEDICINE MicuRx Pharmaceuticals Following the Innovation Path to Combat Infective Diseases Zhengyu Yuan, Ph.D. Co-founder, CEO MicuRx Pharmaceu□cals March Issue 09 2023 Good N utr□ion can be the Savior of Your Life Note Ed t or ’s n today’s world, where infectious diseases significantly Ithreaten our health and well-being, embracing a life of wellness has become essential. The availability of in- demand anti-infective medicine brands play a crucial role in this pursuit, empowering individuals to safeguard their health and lead fulfilling lives. The demand for effective anti-infective medications has grown exponentially with the rise of drug-resistant infections and the ever-evolving nature of pathogens. Antibiotics, antivirals, antifungals, antiparasitics, and vaccines have become indispensable tools in the fight against infectious diseases. These in-demand brands offer hope, ensuring individuals can effectively combat infections and prevent their spread. The first step towards embracing a life of wellness lies in recognizing the importance of preventive measures. Vaccines have emerged as powerful tools in preventing infectious diseases, with highly sought-after brands like the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine leading the way. By embracing vaccination, individuals can protect themselves and contribute to the collective effort to achieve herd immunity. However, despite preventive measures, infections can still occur. This is where the in-demand anti-infective medicine brands play a pivotal role. They provide individuals with the necessary means to regain their health and vitality. As the field of medicine advances, new and emerging brands continue to push the boundaries of anti-infective treatment. Keeping a pulse on these advancements can help individuals stay informed and make informed choices regarding their health. Embracing a life of wellness goes beyond the realm of personal responsibility; it is a collective endeavour. The availability and utilization of in-demand anti-infective medicine brands are crucial in our fight against infectious diseases. By embracing the brands listed in this edition, individuals can proactively protect their health, contribute to disease prevention, and foster a healthier society. Insights Care’s latest edition, 10 Most In-Demand Anti- Infective Medicine Brands of 2023, provides an overview of the importance of in-demand anti-infective medicine brands in promoting a life of wellness. It highlights the significance of vaccines, various anti-infective medications and emerging brands in combating infectious diseases. It also emphasizes the role of these brands in preventive measures, treatment options, and the overall well-being of individuals and society. Hope you have a fantastic read! -Pooja Shah Pja Sh Embracing a Life of Wellness MicuRx Pharmaceuticals 08 Following the Innova□on Path to Combat Infec□ve Diseases Understanding the Importance of An□-Infec□ve Medicines in Modern Healthcare Exploring Insights 20 Aicl Mee□ng the Growing Demand for An□-Infec□ve Medicines Key Brands and Treatment Options 34 Cov Sty Ctts Ekuberg pharma Innova□ng the Pharmaceu□cal Sector 24 38 30 16 How to Ensure Adequate Protein Intake for the Golden-aged People? Basketball and Physical Fitness Rational Vaccines Inc. It’s □me to face herpes CXO Copyright © 2023 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success. Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Insights Care is powered by Insights Success Media and Technology Pvt. Ltd. March, 2023 sales@insightscare.com Follow us on : www.facebook.com/InsightsCare/ https://twitter.com/Insightscare Contact Us: Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - +1614-602-4132 Email: info@insightscare.com For Subscription: www.insightscare.com Insights Success Media and Technology Pvt. Ltd. Survey No.133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027. Phone - India: 7410033802, 8956487823 Email: info@insightscare.com For Subscription: www.insightscare.com We are also available on : Editor-in-Chief Chidiebere Moses Ogbodo Managing Editor Pooja Shah Executive Editor Saloni Agrawal Visualiser David King Art & Design Head Mrunalinee Deshmukh Co-designer Paul Belin Art & Picture Editor Deepanjali Jena Business Development Manager Emily Jones Marketing Manager Bill Thompson Business Development Executives Anna Smith, Jack Miller Sales Executives Mike, Carl, John Technical Head Jacob Smile Assistant Technical Head Prashanth Hiremath Technical Consultants David, Robert Digital Marketing Manager Alina Sege Assistant Digital Marketing Manager Sagar Lahigade SME-SMO Executives Gemson Research Analyst Eric Smith Circulation Manager Tanaji Fartade Description Featuring Person Company Name BioAmp Diagnostics, Inc. bioampdx.com Tara Deboer CEO BioAmp Diagnostics Inc. is committed to preventing the misuse and overuse of antibiotics in healthcare through the development of innovative diagnostic tools, that will give medical providers the information they need to correctly treat an infection. C4Diagnostics c4diagnostics.com Younes Lazrak CEO C4Diagnostics is a French-based biotech specialized in the development of in vitro diagnostic (IVD) tests for human infectious diseases Bold Therapeutics. bold-therapeutics.com Russell McAllister CEO Bold Therapeutics is a clinical stage biotechnology company developing a first-in-class cancer therapy for the treatment of gastric, pancreatic, colorectal and other cancers in combination with existing anti-cancer therapies. Ekuberg Pharma ekubergpharma.com Enrico Giannuzzi CEO For more than 25 years, Ekuberg Pharma has been working in the field of research and development, in the production and marketing of cosmetic products and medical devices especially designed for prevention of gyneacological and dermatological diseases and personal care. EVAXION BIOTECH A/S evaxion-biotech.com Per Norlen CEO EVAXION BIOTECH A/S a clinical-stage AI-immunology™ platform company using its proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Formosa Pharmaceuticals, Inc. formosapharma.com Erick Co CEO Formosa Pharmaceuticals, Inc. is a late-preclinical and early clinical stage biopharmaceutical company with focus in ophthalmology, oncology, and anti-microbial indications. Felix Biotechnology felixbt.com Robert McBride CEO In collaboration with researchers at Yale University and UC Berkeley, Felix Biotechnology is focused on accelerating the deployment of novel biotherapeutics targeting urgent microbial challenges in human health and beyond. MicuRx micurx.com Zhengyu Yuan, Ph.D. Co-founder, CEO MicuRx Pharmaceuticals is a biotechnology company based out of Foster City, California USA and Shanghai, China. Qpex Biopharma, Inc. qpexbio.com Michael Dudley President, CEO Qpex Biopharma, Inc. is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care. Rational Vaccines rationalvaccines.com Agusn Fernandez CEO Rational Vaccines is a preclinical stage herpes vaccine development company actively working to improves lives with the hope of revolutionizing the treatment, prevention and diagnosis of herpes and herpes-related diseases worldwide. 10 Most In-Demand An□-Infec□ve Medicine Brands of 2023 Zhengyu Yuan, Ph.D. Co-founder, CEO MicuRx Pharmaceu MicuRx Pharmaceuticals Following the Innovation Path to Combat Infective Diseases Cover Story We are not only developing new drugs but also be□er drugs that are able to address clinical problems which exis□ng treatments may not be able to solve. 10 Most In-Demand An□-Infec□ve Medicine Brands of 2023 long the evolutionary thread of human Adevelopment, health care has been the most sensitive node that demands keen attention. With many diseases, pandemic and outbreaks unfolding over the globe, the pathogenic impact has grabbed global attention. Microbes – although essential to human life – are tricky because they evolve rapidly. While some spread with a great publicity, like COVID-19, others are silent yet critically impactful. In the past decade, humans have been edged into a "silent pandemic" caused by bacterial resistance. In 2019, approximately 4.95 million (3.62-6.57) deaths were estimated to be related to Antimicrobial Resistance (AMR), with 95% of the deaths, i.e. 1.27 million deaths, attributed directly to it, as per the global Antibacterial Resistance collaborators. Clearly, new treatments are needed, especially those that would decrease the burden of antimicrobial resistance, have a low potential for adverse events, and be relatively convenient to use. MicuRx Pharmaceuticals, a pioneering company founded in 2007, addresses the need to come up with new antibiotics. Through consistent research, the company develops innovative therapeutics and beneficial drugs which addresses unmet medical needs. We had the exclusive chance to interview MicuRx's veteran visionary Co-founder and CEO, Zhengyu Yuan, Ph.D., where he discussed the successful journey of a pharmaceutical startup company from early R&D through launch of their own medicines. Along with it, he shared some exclusive insights about the industry along with his healthcare perspective of the pharmaceutical community. Let's explore the story of MicuRx through the following interview. Zhengyu, please brief our audience about MicuRx. Kindly tell us the source of inspiration for venturing into the medical industry. In the early 1980s, when I first came to the US for my post- graduate study at Cornell University, I learned the fascinating story of how ACE inhibitors (for blood pressure control) were "rationally designed" using new advances in chemistry and biology. These drugs eventually became lifesavers for millions. Rational drug design means we can find a drug not by chance but by our own wisdom and skill using a more efficient, modern approach. I told myself then: I want to do that! Tell us about yourself and shed some light on your journey as the CEO of MicuRx. By 2005, there were two trends that became obvious: multidrug-resistant (MDR) bacteria became a bigger problem in our society. But ironically, pharma companies were either exiting or on their way to exiting the antibacterial field. Therefore, the need for novel drugs against MDR bacteria would become a true "unmet clinical need." We believe that this crisis offered both challenges and opportunities, and we were passionate about contributing to solutions. Yet despite the challenges, MicuRx has made steady progress from R&D to commercialization. Can you elaborate upon the core values on which MicuRx is built and what is the mission of the company? MicuRx's motto is "Better Therapy Through Superior Medicines." We are not only developing new drugs but also better drugs that are able to address clinical problems which existing treatments may not be able to solve. We provide new options to physicians and patients with clear benefits. And we keep doing what we are good at in the focused area of infectious diseases, with the aim of building a company that people trust and respect. MicuRx was one of the first start-up pharmaceu□cal companies to have a trans-Pacific business model. What unmet patient medical needs did you identify that drove you to establish MicuRx? After working in the antimicrobial field for ten years at Vicuron, I realized that finding an antimicrobial that is effective is not the hardest challenge. The hardest challenge is developing an antibiotic that is safe because, not surprisingly, drugs that kill bacteria often cause safety problems for humans. Safety concerns can limit the use of very effective antibiotics. One very crucial product, called linezolid (Zyvox®) currently commercialized by Pfizer, is an important drug to treat resistant Gram-positive bacteria. But linezolid has well-known hematological toxicity, which typically limits use of the product to less than fourteen days. Although linezolid became a blockbuster, it could have been even more widely adopted if the safety profile had been better. An improved safety-to-efficacy profile is especially important for infections that can be treated in the outpatient setting for less severe infections in otherwise healthy adults. A second need is to have oral antibiotics effective against resistant pathogens to avoid or reduce the need for hospitalization. Many antibiotics effective against drug- resistant bacteria are available only in intravenous (IV) formulations that require hospitalization or daily visits to an outpatient infusion clinic.We wanted to create an antibiotic which has flexibility to be used in hospital as an IV or in the outpatient setting as an oral tablet. Contezolid is an oral antibiotic with very potent antimicrobial activity against two important Gram-positive resistant pathogens that cause a variety of infections: methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Oral contezolid is well suited for the millions of skin infections, diabetic foot infections, and other infection types that need treatments with potent activity against MRSA and a better safety profile without needing to be hospitalized. How has technology been leveraged in MicuRx's drug discovery and screening? What processes support MicuRx's products to attain maximum value and high success rates while maintaining lower costs? First, we established corporate operations that were very unique at the time and that have been copied numerous times since as a new best practice: trans-Pacific operations. MicuRx leads research and development from our offices in California and conducts research in both the US and the established laboratories in Shanghai, China. Our goal was to conduct research using international standards supported by China's lower cost structure and rapid response time. MicuRx was one of the first start-up pharmaceutical companies to have a trans-Pacific business model. Second, we set up our R&D process to ensure the critical parameters were addressed from the beginning. We believe a successful antibiotic will be a drug with good efficacy, safety, and a low tendency to develop resistance, which are the major reasons causing failures in clinical trials. Therefore, at the beginning of our discovery program, we set up potency and toxicity test models to evaluate the compounds we designed to achieve the best balance of benefit to risk. MicuRx has its own BSL-2 lab, so we can efficiently conduct microbiological studies including drug resistance studies. We look for potent compounds that also have safety improvements to provide a well-balanced drug profile. MicuRx has a strong team of scientists to ensure the delivery of drug candidates that meet our goal. We also leverage externally contracted organizations with verified quality systems to conduct GxP studies. This process at the screening and development stages reduces the risk of failure in clinical development in a cost-effective way. How do MicuRx's products manage to address the unmet needs of patients? First, MicuRx has a goal to address medical needs that are not adequately addressed by currently available therapies. Then we conduct targeted drug discovery to create new compounds. Our first antibiotic, contezolid,was developed to reduce safety risks for an oxazolidinone antibacterial while preserving effectiveness in treating infections caused by multidrug-resistant bacteria. Specifically, improving hematological safety compared to linezolid was a key goal of the contezolid program. Success followed, and contezolid tablets were approved for complicated skin and soft tissue infections in China in 2021. International clinical trials are currently underway for contezolid and its intravenous prodrug, contezolid acefosamil, in acute bacterial skin and skin structure infections, and diabetic foot infections. Our new programs in anti-infectives and other therapeutic areas will take the same approach of identifying unmet medical needs and creating new drugs to address them to improve patient outcomes. How has the approval of MicuRx's first drug, contezolid, led to a new journey of novel anti-infective drugs in China? China is both the largest manufacturer and consumer of antibiotics in the world. So antimicrobial resistance is high in China. However, very few new antibiotics were Improving hematological safety compared to linezolid is a key goal of the contezolid program. Dr. Zhengyu Yuan is the Co-founder and Chief Execu□ve Officer of MicuRx. With over 30 years of experience in drug discovery and development, focusing on novel an□bio□cs, and more than 30 publica□ons in peer-reviewed scien□fic and pharmaceu□cal industry journals, he is responsible for the overall control of MicuRx's strategic development and pipeline layout. Prior to MicuRx, Dr. Yuan was senior vice president of Vicuron, responsible for the corporate discovery and early drug development. Vicuron developed the an□bacterial drug dalbavancin (Dalvance®) and the an□fungal drug anidulafungin (Eraxis®). Vicuron went public on Nasdaq in 2000 and was acquired by Pfizer in June 2005 for $1.9 billion, which was the largest deal in an□microbial development that year. Prior to Vicuron, Dr. Yuan also held various management posi□ons at Syntex and Affymax. Dr. Yuan holds a Ph.D. in Biophysical Chemistry from Cornell University. Awards & Recogni□ons Ÿ Contezolid received QIDP (Qualified Infec□ous Disease Product) status from the FDA for Acute Bacterial Skin and Skin Structure Infec□ons (ABSSSI), and was granted Priority Review status by the NMPA (Na□onal Medical Products Administra□on, i.e., the Chinese equivalent of the FDA). Ÿ Once contezolid was approved by NMPA, it was listed on the China NRDL (Na□onal Reimbursement Drug List, which is a na□onal formulary) within one year, which is extremely quick. The Veteran Leader initially discovered in China; most research is done in the US or the Europe. So, the approval of contezolid as a MDR antibiotic drug actually developed in China, is a major milestone. This approval gives MicuRx an opportunity to evolve into a commercial-stage company. We have built a dedicated commercial team that has a lot of experience in the commercialization of new antibiotics in China. As the original developer of this drug, MicuRx has the advantage of being able to contact and respond to key opinion leaders and physicians in an effective way. MicuRx has also started to work with clinical experts to improve awareness of antimicrobial resistance and clinical practice for infections caused by MDR bacteria. Zhengyu, Please describe the trailblazing corporate approach the company took to go from research, discovery, clinical and regulatory approval, and ultimately commercialization in China's first global market. MicuRx is deeply rooted in China, with the majority of our research and all of our commercialization team currently based there. With a good understanding of the local market practice and wide connections with KOLs, suppliers, and business partners, our team has successfully transformed MicuRx China from a pure research center into a fully functional pharmaceutical company. With our first drug approved in China and our IPO in the China STAR market in August of last year. China becomes the financial and strategic driving force for MicuRx's global business. What advice would you like to give to budding entrepreneurs and enthusiasts aspiring to venture into the medical industry? Never give up! You will have a lot of failures and difficult times, and sometimes it even looks impossible to move forward. Only those who persist will successfully reach the other side. How do you envision scaling your organization's services and operations in 2023 and beyond? In addition to bacterial infections, the business of MicuRx will expand to a broader range of infectious diseases, including fungal and viral infections. We believe there are many unmet medical needs due to diseases caused by these other pathogens. With the growth of drug resistance, the use of immunotherapy, and an ageing population, the need for better therapy will continue to increase. And no doubt, the world needs to be prepared for the next pandemic as well. As a commercial stage company, we will also actively contribute to public health policy development and improve infection management in both the community and the hospital. MicuRx will always follow our mission to deliver "Better Therapy Through Superior Medicine" for infective diseases. he most crucial part of the existing society is the Tneed for medical attention toward big and small problems. The speedily changing technology and the world knows the importance of healthcare and strive for the betterment of the same. Researchers have been conducting various experiments for coming up with innovative solutions that are being implemented constantly to create a safer environment and ensure a better future. Having a similar goal of providing innovative solutions for well-being is Ekuberg Pharma. With its years of experience in the field, it has been leading the healthcare sector toward a better path, and mankind, toward a secure future. The visionary behind this prestigious organization is its exceptional CEO, Mr. Enrico Giannuzzi, who holds the command and drives Ekuberg Pharma toward astonishing heights. What are these innovative solutions? Let us enroll to find out. Insights and About Ekuberg Pharma is an Italian, family-run company with 30 years of experience. It has been working in the field of research and development, in the production and marketing of cosmetic products and medical devices specially designed for prevention and personal care. Ekuberg Pharma’s activity focuses on different therapeutic areas such as gynecology, dermatology, otolaryngology, pediatrics, trichology, and wound care. Mr. Enrico Giannuzzi, the second-generation CEO of Ekuberg Pharma, says, “Nature always has the solution, and science must reveal it. This is our vision.” Primary Goals Ekuberg Pharma’s mission is to always find a natural solution to the most common disorders affecting skinhealth and rare, chronic diseases, with the valuable support of healthcare professionals in many therapeutic areas and through educational activities and informative campaigns. In the last years, Ekuberg Pharma’s researchers focused on diabetes and oncological fields, aiming to find effective treatments to heal diabetic foot and chronic wounds. “Our in-depth knowledge of active ingredients derived from medicinal plants is crucial to create valuable products for HCPs and patients who rely on our expertise. This is the key to our innovative Lecoxen,” explains Mr. Giannuzzi. Evolutionary Process Lecoxen entails an innovative protocol of advanced medication for wounds, which accelerates skin healing with great effectiveness, the main reason being the medical plants in the formula. The researchers tested its efficacy in vivo on diabetic feet, bedsores, oncological wounds and scleroderma ulcers. Diabetes is the primary worldwide metabolic disorder that affects millions of people and will affect even more young people in the following years due to EKUBERG PHARMA 10 Most In-Demand An□-Infec□ve Medicine Brands of 2023 Innovating the Pharmaceutical Sector 16| March 2023|www.insightscare.com The widespread use of botanical extracts in medical activities is not a mere trend for Ekuberg Pharma, it also represents the evolution of science and the discovery of nature's power. Enrico Giannuzzi CEO Ekuberg Pharma 17| March 2023|www.insightscare.com The outcomes of studies proved Lecoxen efficacy in improving wound healing, as a natural ally in wound treatment, and as a cheap, fast and effec□ve way to enhance the quality of life in pa□ents with chronic wounds. Preserving human life and health is the goal of Ekuberg Pharma and firmly wants everyone to share the same goal in an accurate and accessible way. ® ® 18| March 2023|www.insightscare.com unhealthy lifestyles, unbalanced diets and genetics. Conversely, in recent years, appropriate treatment for this disease increased average life expectancy. Mr.Giannuzzi points out, “The elderly, particularly diabetic and oncological patients, deserve to live better in the second part of their lives.” Ekuberg involved all its R&D resources and clinical board surgeons, rheumatologists, and dermatologists to study the unmet need for wound treatment in these patients, the causes of healing delays, and to find viable solutions through a holistic approach to health by putting human health at the center of the action. The widespread use of botanical extracts in medical activities is not a mere trend for Ekuberg Pharma, it also represents the evolution of science and the discovery of nature's power. Ingenious Treatment Ekuberg Pharma has innovated wound healing treatment with a two-step protocol for greater effectiveness and a better quality of life. The first step is wound hygiene, made by a sterile seawater spray designed to clean and cleanse the wound with mechanical action and chemical activities due to trace elements of seawater which help improve the cicatrization processes. Only a clean wound can heal correctly. The second step of the Lecoxen protocol is Lecoxen cream, the first advanced medication with an exclusive formula based on vegetal antioxidant extracts with known pharmacological activities. The reason being its innovative water-in-silicone formula, Lecoxen cream creates the best conditions for the wound environment to accelerate healing by reducing inflammation and protecting perilesional skin. Moreover, in-vitro tests proved Lecoxen’s efficacy in boosting epithelial and endothelial healing with no cytotoxic effects. Currently, the organization is carrying out many clinical trials and the first stage of analysis has shown significant improvement in wound healing through different chronic stages for patients and HCPs. 19| March 2023|www.insightscare.com 20| March 2023|www.insightscare.com Medicines in Importance of Healthcare n modern healthcare, the importance of anti-infective Imedicines cannot be overstated. These medications play a crucial role in treating and preventing infectious diseases, which continue to pose significant global challenges to public health. By exploring insights into the role of anti-infective medicines in modern healthcare, we can better understand their significance and impact. Anti-infective medicines encompass a diverse range of therapies, including antibiotics, antivirals, antifungals and antiparasitic drugs. They are specifically designed to target and eliminate infectious agents such as fungi, bacteria, parasites and viruses. These medications are essential in alleviating symptoms, curing infections and saving lives. They are utilized across various healthcare settings, including hospitals, clinics and community pharmacies, and are prescribed for both acute and chronic infectious conditions. Anti-Infective Insights One key insight is the crucial role that anti-infective medicines play in mitigating the spread of infectious diseases. By promptly diagnosing and treating infections, healthcare providers can limit the transmission of pathogens within communities, prevent outbreaks and protect vulnerable populations. These medications also contribute to preventing complications and reducing the overall burden of disease, ultimately leading to improved patient outcomes and reduced healthcare costs. However, the growing challenge of antimicrobial resistance presents a significant threat to the effectiveness of anti- infective medicines. The misuse and overuse of these medications contribute to the emergence of drug-resistant strains of microorganisms, rendering existing treatments less effective or ineffective altogether. Addressing this global health issue necessitates a comprehensive approach that involves promoting responsible prescribing practices, strengthening surveillance systems, supporting research and development for new therapies, and educating healthcare professionals and the public about the proper use of these medicines. Another critical insight is the continuous need for research and innovation in the field of anti-infective medicines. The 21| March 2023|www.insightscare.com Exploring Insights dynamic nature of infectious diseases requires ongoing efforts to develop new drugs, enhance existing therapies and explore alternative treatment options. This involves understanding the mechanisms of action of pathogens, identifying new targets for drug development, and conducting rigorous clinical trials to evaluate safety and efficacy. Research in this field also encompasses investigating combination therapies, immunotherapies and novel treatment modalities to address emerging infectious challenges. Collaboration and partnerships among various stakeholders are paramount in tackling the complexities associated with anti-infective medicines. Pharmaceutical companies, healthcare organizations, research institutions, regulatory authorities, and policymakers must work together to promote research, ensure access to effective treatments and develop policies that incentivize the discovery and development of new anti-infective medicines. Global initiatives, such as the World Health Organization's Global Action Plan on Antimicrobial Resistance, play a crucial role in coordinating efforts, raising awareness and driving policy changes to combat antimicrobial resistance at a global scale. Importance of Anti-infective Medicines The importance of anti-infective medicines in modern healthcare extends beyond the treatment of individual patients. It has significant implications for public health, the economy and overall societal well-being. By continuing to explore this topic, we can delve deeper into the multifaceted aspects of anti-infective medicines and their impact on healthcare systems. One crucial aspect to consider is the role of anti-infective medicines in preventing the spread of infectious diseases. Vaccines, a type of anti-infective medicine, have been instrumental in eradicating or reducing the burden of many infectious diseases, such as polio, measles and hepatitis. Vaccination programs have played a pivotal role in protecting populations, particularly vulnerable groups such as infants, the elderly, and immune-compromised individuals. By immunizing individuals, anti-infective medicines help create herd immunity, thereby reducing the overall transmission of pathogens within communities. Another significant insight is the importance of appropriate prescribing and stewardship of anti-infective medicines. Healthcare professionals have a responsibility to ensure the judicious use of these medications to minimize the development of antimicrobial resistance. Antimicrobial stewardship programs promote optimal prescribing practices, including appropriate selection, dosage and duration of treatment. By implementing such programs, healthcare providers can help preserve the effectiveness of existing anti-infective medicines and prolong their usefulness in combating infections. Furthermore, the economic impact of infectious diseases cannot be ignored. Outbreaks of infectious diseases can lead to substantial healthcare costs, loss of productivity and strain on healthcare infrastructure. Anti-infective medicines play a vital role in reducing the severity and duration of infections, thus mitigating the economic burden associated with healthcare utilization and missed workdays. By effectively treating and preventing infectious diseases, anti- infective medicines contribute to the overall productivity and stability of economies. To Conclude: In conclusion, understanding the importance of anti- infective medicines in modern healthcare requires exploring insights into their role in mitigating the spread of infectious diseases, addressing antimicrobial resistance, promoting research and innovation and fostering collaboration among stakeholders. By recognizing the significance of these medicines and implementing comprehensive strategies, we can effectively combat infectious diseases, improve patient outcomes and safeguard public health for generations to come. -Pooja Shah 22| March 2023|www.insightscare.com How to Ensure Intake for the Golden aged - People? Adequate Protein By- Fred Bergmans dequate protein intake among elderly is a growing Aconcern in healthcare. At the beginning of this century scientific studies signaled malnutrition in affluent countries up to 25% with hospital patients. Disease related protein deficiency due to acute or chronic diseases or decreased appetite and frailty were identified as the main causes for malnutrition. General dietary advice focused on adding high protein snacks and oral nutritional supplements to the daily menu. The disappointing result was that still less than 50% of hospital patients would not meet the recommended protein intake. A consortium, lead by Wageningen University and Research, started in 2012 to develop a new nutritional strategy and products to solve malnutrition. Scientific studies revealed that the standardized care focused both on supplementation of energy and protein. As satiation was the barrier for higher protein intake the current practice of both energy and protein supplementation did not work. To solve this problem, new products were developed, focusing on protein enrichment instead of energy density. These products were familiar basic foods, like bread and pastry, fruit juice and soups, and ice-cream and small meals. Al these products were tested in the foodhospital Gelderse Valley, in residential care and among patients at home. RCT studies concluded that 79% of patients reached the recommended protein intake. This study shows that the new nutritional strategy works: substitution instead of supplementation. Substitute regular basic nutrition with protein enriched basic nutrition. The essence of the substitution strategy is the range of familiar products people like to eat, replaced by the same products containing 2 to 4 times the amount of protein, tasting equally as good as their reference products. The range of protein enriched products fits in all eating moments of the day. Spreading the intake in 3 main meals and 3 in-between moments results in an optimal protein intake per moment and the highest intake per day. This was all confirmed by RCT studies. In 2015 Carezzo Nutrition, a start-up partner of the consortium introduced this range of products in the Dutch market. The success of the strategy was confirmed by winning the Accenture Innovation Award for Fair Food, and scientific proof of the effectiveness of the new nutritional strategy of substitution was presented. We first entered the Dutch hospital market, which welcomed the good taste of these familiar products and the high protein density versus regular protein-rich food. It also adds to the quality of life as these products fit in regular eating habits and do not look like medicine. 24| March 2023|www.insightscare.com Since hospital length of stay gets shorter, 'better in is better out' gets more important. Improving patients' nutritional condition before hospitalization and after discharge, called prehabilitation and rehabilitation, is seen as a direct contribution to efficacy of medical treatment. Less complications, shorter length of stay and successful recovery potentially leads to increased benefits at decreased costs. A RCT study on pre-operative nutritional support on senior patients scheduled for heart surgery was conducted by Nina Zipfel PhD in collaboration with Carezzo. Participants received Carezzo products at home during 2 weeks. Their protein intake increased by 50-100%, due to the protein enriched products and the high motivation to self-manage nutritional condition improvement. The group of people with a protein deficiency is much larger than discussed so far. Frail elderly people with low appetite tend to eat less. Since they are less physically active their portions get smaller and so does the energy intake. However, their protein intake recommendation is not related to their activity, but to their body composition. Knowing that their protein recommendation is 25% higher than that of young adults, there is a high risk of protein malnutrition. In practice we see that it is hard to finish a full hot meal, and that 10-20% is left behind on the plate, or worse one meal is consumed in two days, shared with a partner or thrown in the trash. Protein intake then drops under 20 g, as regular meals (500 g) contain 20-25 g protein. Carezzo developed small meals of 350 g, containing 30 g of protein. Fred Bergmans is Co-founder of Carezzo Nutri□on, a Dutch start-up for protein enriched food & drinks for malnutri□on. Fred started his marke□ng career in food companies, like Heineken, Mars, Kra□ Foods and Perfe□/van Melle. He founded an innova□on strategy consultancy, where he first met the problem of malnutri□on in healthcare. Passionately he founded Carezzo Nutri□on. Author Bio Fred Bergmans, Co-founder, Carezzo Nutrition 25| March 2023|www.insightscare.com There is a challenging goal, also for Carezzo, to improve the protein quality of plant-based products also for the older aged groups. We will develop new products combining fruit, vegetables and hybrid proteins. We now have 80% of all Dutch hospitals as clients, which is a fast-track record in institutional healthcare. It shows that the new nutritional strategy is well accepted. Unfortunately, due to healthcare insurance and governmental regulations, there is no level playing field with oral nutritional supplements. There is no reimbursement on Carezzo products by health care insurances, so people do not have an equal choice. The 'Food as Medicine' theme acknowledges the importance of the functionality of food in the prevention and treatment of lifestyle related diseases. There is a huge opportunity to change towards 'the food solution' and reduce healthcare costs while improving the quality of life. As a society we should embrace innovation to improve healthcare: Ÿ The technological innovation for better food products Ÿ The social innovation for faster implementation Ÿ The governance innovation to reduce barriers in finance and regulation We are committed to transfer academic insights into good tasting functional food products, that is our practice. We are deeply touched by the gratitude of patients that finally reach their desired protein intake, because that is our purpose. Protein enriched products fit in maintaining the dietary habits. Just change products to address the different protein recommendations due to different circumstances. To serve patients at home the Carezzo webshop was opened which facilitates the substitution strategy in the home setting and patients could continue the use of the products they received in the hospital during the total period of medical treatment; pre and post included. The webshop also serves people with chronic diseases, such as age related malnutrition, sarcopenia and COPD, which already used Carezzo products for multiple years. The combination of global trends 'better for the environment = better for your health' boosts the shift towards plant-based products, reducing meat and dairy consumption. The protein quality for golden-aged people is, however, a major concern. The advice for them is to not go Vegan. Protein quality, defined by the amount and completeness of essential amino-acid profile, from plant- proteins is lower than the quality of animal-based proteins. 26| March 2023|www.insightscare.com Check should be drawn in favor of : INSIGHTS SUCCESS MEDIA TECH LLC www.insightscare.com Subscribe Today Never Miss An Issue Stay in touch. Subscribe to Insightscare Get Insightssuccess Magazine in print, & digital on www.insightscare.com Corporate Office Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin,OH 43017, United States Phone - (614)-602 - 1754,(302)-319-9947 Email: info@insightscare.com For Subscription : www.insightscare.com ymptoms of painful blisters or ulcers in an infected Sarea affect billions of people who are diagnosed with the herpes virus. In addition, many patients experience debilitating neuralgia, skin split, fissures, fever, chills, erythema, minor abrasions, and myalgias. Not only do these patients experience pain and discomfort, but also the social consequences associated with isolation and stigma. But despite being a serious health concern, there has been no cure for the infection. This has led to an urgency for the development of better treatment and prevention, particularly vaccines. Emphasizing such an opportunity, Rational Vaccines is committed to ending the herpes pandemic. It is an investigational-stage infectious disease company that is focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections. Using its proprietary technology, Rational Vaccines creates genetically engineered replication-controlled herpes vectors as safe therapeutic and prophylactic vaccines against herpes type 1 and 2. These modified viruses have been also tested preclinically to deliver cancer vaccines and vaccines against other infectious diseases. In an interview with Insights Care, Agustin Fernandez III, the CEO of Rational Vaccines shares the journey from addressing the severity of herpes to innovating therapeutic solutions against the infection. Following are the excerpts from the interview. Kindly tell us the source of inspiration. What led you to venture into the Anti-Infective Medicine Industry? Like nearly five billion other people, I suffered from oral/facial HSV1 infection. For me, and for millions of other patients, the current standard of care i.e., the 50-year- old antivirals, was completely ineffective. More than 20% of patients suffer from a variety of symptoms, beyond skin outbreaks, that include nerve pain in various parts of the body and brain inflammation that is thought to be a source of brain degeneration and dementia (Alzheimer’s). I began this journey, by first studying virology and immunology and subsequently co-founding Rational Vaccines (RVx) to solve a very personal problem. Soon I learned that I shared this problem with over a billion people worldwide and so many others suffer in very severe ways. Not only from the chronic and debilitating sores the virus can cause, but many herpes patients deal with—exacerbated HIV infections, infant mortality due to herpes, and even herpes-induced blindness. What started as an effort to help myself has morphed into a mission for the company to help millions of people suffering from herpes. Brief us about yourself and shed some light on your role and responsibility at the company. As the Co-founder and CEO, my main goal is to support the science and the amazing scientists at Rational Vaccines that have cracked the code to this virus and are poised to deliver both therapeutic and preventative vaccines for what may be the oldest virus plaguing humankind. I conducted several rounds of funding ($41 million), directed the engineering of a new mutant HSV-2 virus, acquired the rights to a mutant HSV-1 virus in collaboration with Dr. Kousoulas of LSU, supervised the GMP production of vaccine vials for the upcoming clinical trials, and organized the preparation of dossiers for regulatory agencies in the UK and the US. What are the mission, vision and values shared by the company? Our mission is to eradicate herpes simplex. And the vision is to create prophylactic vaccines, to protect individuals not RATIONAL Vaccines Inc. It’s □me to face herpes 10 Most In-Demand An□-Infec□ve Medicine Brands of 2023 30| March 2023|www.insightscare.com Agus□n Fernandez CEO 31| March 2023|www.insightscare.com yet infected, as well as therapeutic vaccines to reduce the reactivation of the viruses and alleviate symptoms in patients already infected. Our values include transparency, a sense of urgency, an appetite for collaboration, and an aspiration to serve all patients in need around the world. Our focus is Patients, Patients and Patients. Sadly, herpes affects nearly everyone, either directly or indirectly through loved ones suffering. The team at RVx has recognized this problem and has chosen to not turn a blind eye. We forego trends and ignore the media. Our only true north is finding and following the best science to battle this virus and its corresponding diseases. At Rational Vaccines, we were working on vaccines before vaccines were a cause célèbre. We know that replication- competent vaccines are the only solution to the herpes problem, and we stay focused on this truth, by resisting the temptation to follow the herd of failed attempts into the subunit, killed, inactivated, or antigen-specific mRNA vaccine fields. Trends come and go in science, as in any other field. We are convinced that our technology is the only one that will truly help patients to prevent this virus from infecting and from reactivating if already infected and we stay on course. All that matters at RVx is what will best serve the patient. We were founded by patients, we are supported by patients, and we are led by patients and patient-centric team members. Tell us about the core products and services that the company offers to support the needs of the clients/patients. How are these different from other companies in the market? Our vaccines are based on live, replication-limited viruses engineered for safety. This a long explanation but every word counts, using a live virus that can replicate is the only approach that has worked so far in this family of viruses, as demonstrated by the vaccine for chicken pox (HHV3 is a virus of the same alpha herpes virus family). Instead of old approaches of “attenuation” by “passaging”, we genetically engineer our viruses to be safe. More precisely, they cannot establish latency in the nervous system, and they cannot escape being suppressed by the human immune system as “wild viruses” can both do. Brief us about the rising need for Anti-Infective medicine in the healthcare sector. How will it impact the way patients receive treatment and the clinical decisions taken by care providers? Today there is no vaccine approved for herpes and many attempts have failed because researchers tried to use other technologies that do not present the entire spectrum of the 75 epitopes of the virus-like our products do. The only therapeutic treatments are half-a-century-old antibiotics that do not provide satisfactory relief to a large percentage of patients and may cause side effects. By the way, there is no good diagnostic available either and we have patents in that segment. Our vaccines cover therapeutic and preventative vaccines. Addressing both sides is the best way to reduce the burden of disease. In the case of herpes, the same mode of action that keeps the virus from infecting in the first place is responsible for controlling the reactivation of this virus in patients that have HSV1 or HSV2 latent in their nervous system. This is why we are deploying this technology both to prevent and treat herpes. What specific R&D operations is your company leading at present? Why do you find them essential in developing or improving anti-infective solutions? We are currently preparing a Phase II clinical trial under an accelerated approval program for our therapeutic vaccine. We believe that data from this trial will also support the advancement of our prophylactic candidate. Our mission is to eradicate herpes simplex. And the vision is to create prophylac□c vaccines, to protect individuals not yet infected, as well as therapeu□c vaccines to reduce the reac□va□on of the viruses and alleviate symptoms in pa□ents already infected. 32| March 2023|www.insightscare.com We are also exploring deploying these very safe and stable viral vectors which have roughly 6 times the “payload” capacity of currently available viral vector platforms as a delivery system for a broad range of infectious diseases as well as cancer vaccines. In what way do you consider technological advances to be a pathway in conducting your company’s operations? Our development of products would have not been possible without the incredible advancements in molecular biology. In the past, when live-attenuated vaccines were deployed, scientists didn’t have the tools to genetically engineer mutants with very specific and safe properties in the way we do today. Old technologies resulted in efficacious vaccines—with the fear that they could revert and or cause vaccine-derived disease. Using the latest technologies, we can create a mutant that was never a virulent wild-type strain. A mutant that behaves exactly how we intend it to. For example, we have made our vaccines sensitive to the interferon response—the first line of defense of the immune system. Our vaccines are cleared out by the recipients in a few days. We have seen this unequivocally in our studies. What endeavors is the company currently pursuing to improve its service measures for the clients/patients? We are and always have been involved in a worldwide education and advocacy campaign. Herpes is a virus that is too often ignored by government agencies and sometimes even by general practitioners. There is a belief among some that the old antivirals available have solved the herpes problem. They have not. We have run several patient engagement and epidemiology studies that illustrated the huge unmet needs and burden of disease. For example, a recent study shows that over 55 percent of patients still experience recurrent herpetic disease (outbreaks) even while on daily suppressive therapy with antivirals. What advice would you like to give to budding entrepreneurs and enthusiasts who desire to venture into the industry? Our main piece of advice would be to never give up. Pick a problem that needs solving that no one else is addressing correctly and ask yourself: If not me, then who? If not now, then when? If the mission that you are fighting for is greater than any discomfort you can imagine going through, then, you will get up every morning with your team and meet the obstacles that always come when you truly want to bring about change. Don’t ever think of money, or personal success, only ask yourself: Does the world need this problem solved? Will I leave this place better than how I found it if we can rise to this challenge? If the answer is yes to you, then go all in and don’t let anything take your eye off that goal. How do you envision scaling the company’s services and operations in 2023 and beyond?  In 2023, Rational Vaccines is heading full force into clinical development and scaling up manufacturing of our vaccines in preparation for upcoming commercialization. Please mention client testimonials or recognitions that your company may have attained along its journey to success. Let’s listen to a patient. “I received what some call “The Gift” eleven years ago. 80% of people who have it don’t even know they have it and since they don’t know, they are out there spreading it. But unfortunately for me, I am one of those who suffer chronically from it. For me, it was sort of like having a sunburn with intense neuralgia. This neuralgia is the same type people get from shingles. I had to take high doses of antivirals to try to keep it under control and sometimes it would still break through. The antivirals made me tired. I thought my love life was over when I found out that antivirals only reduce the risk of transmissions by 49%. I was so scared of passing it on that I couldn’t be in relationships. It can mess with your mind when you suffer quite a bit from it. I have met some amazing people in the same boat along the way, doing a great amount of volunteer work. We have talked with hundreds of people out of suicide. Sometimes I fail. I lost one amazing young woman to suicide that I had become close to. There was one man who jumped off a bridge. The supposed accidental shooting of another young woman. And one of the saddest things I have seen was the ultrasound of an 8-month-old fetus that was missing its brain. Then there are the people who stop living. They think they are damaged goods and will never have love or a family.” 33| March 2023|www.insightscare.com Anti-Infective Medicines Meeting the Growing Demand for 34| March 2023|www.insightscare.com The demand for anti-infective medicines has steadily increased due to the rising prevalence of infectious diseases worldwide. As healthcare providers strive to meet this growing demand, it becomes crucial to understand the key brands and treatment options available in the market. In this article, we will explore some prominent brands and treatment options for anti-infective medicines, focusing on antibiotics, antivirals, antifungals and antiparasitics. I. Antibiotics: Fighting Bacterial Infections Penicillins Penicillins are a class of antibiotics that have been widely used for decades. Brands such as Amoxicillin, Ampicillin and Penicillin G are effective against various bacterial infections. They work by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. Penicillins are commonly used to treat respiratory tract infections, skin and soft tissue infections, and urinary tract infections. Cephalosporins Cephalosporins are another important class of antibiotics. They have a broader spectrum of activity compared to penicillins and are commonly used when penicillin resistance is suspected. Brands such as Cephalexin, Ceftriaxone and Cefotaxime are frequently prescribed for respiratory tract infections, urinary tract infections, and complicated skin and soft tissue infections. Macrolides Macrolides, including brands like Azithromycin, Clarithromycin and Erythromycin, are commonly used as penicillin alternatives. They inhibit bacterial protein synthesis and are effective against respiratory tract infections, sexually transmitted infections, and skin infections caused by certain bacteria. Key Brands and Treatment Op□ons 35| March 2023|www.insightscare.com II. Antivirals: Targeting Viral Infections Oseltamivir Oseltamivir, marketed under the brand name Tamiflu, is a widely used antiviral medication for treating and preventing influenza. It works by inhibiting the neuraminidase enzyme, which is crucial for viral replication. Oseltamivir is most effective when administered within 48 hours of symptom onset and is recommended for high-risk individuals, such as older people and those with underlying medical conditions. Acyclovir Acyclovir is an antiviral drug used primarily to treat herpes simplex virus infections, including genital herpes and cold sores. It inhibits viral DNA synthesis, preventing viral replication. Acyclovir is available in various forms, including oral tablets, topical creams, and intravenous formulations for severe cases. Tenofovir/Emtricitabine The combination of Tenofovir and Emtricitabine, marketed as Truvada, is widely used for pre-exposure prophylaxis (PrEP) in individuals at high risk of acquiring HIV. This antiviral combination inhibits the reverse transcriptase enzyme, which is essential for viral replication. Truvada has been instrumental in preventing new HIV infections and is recommended for individuals engaging in high-risk behaviors. III. Antifungals: Treating Fungal Infections Fluconazole Fluconazole is a widely used antifungal medication for the treatment of various fungal infections, including vaginal yeast infections, oral thrush, and systemic fungal infections. It inhibits fungal cell membrane synthesis, leading to cell death. Fluconazole is available in oral and intravenous formulations, making it convenient for different treatment scenarios. Amphotericin B Amphotericin B is a potent antifungal drug used for severe systemic fungal infections. It works by binding to fungal cell membranes, causing leakage and subsequent cell death. Although it can have significant side effects, Amphotericin B is often a last resort in life-threatening fungal infections when other antifungal agents have failed. IV. Antiparasitics: Addressing Parasitic Infections Artemisinin-based Combination Therapy (ACT) Artemisinin-based Combination Therapy (ACT) is the recommended treatment for uncomplicated malaria caused by Plasmodium falciparum, the most dangerous malaria parasite. ACT combines artemisinin derivatives, such as Artemether or Artesunate, with a partner drug, such as Lumefantrine or Mefloquine. This combination ensures rapid parasite clearance and prevents the development of drug resistance. Albendazole Albendazole is a broad-spectrum antiparasitic drug used to treat various helminthic infections, including intestinal worms like roundworms, whipworms and hookworms. It works by inhibiting microtubule formation in the parasites, impairing their ability to absorb nutrients and causing their eventual death. Albendazole is available as oral tablet and is commonly administered as a single-dose treatment. Conclusion Meeting the growing demand for anti-infective medicines requires a comprehensive understanding of the key brands and treatment options available. Antibiotics, antivirals, antifungals and antiparasitics are critical in combating bacterial, viral, fungal and parasitic infections, respectively. Healthcare providers must stay updated with the latest treatment guidelines and foster responsible use of these medicines to combat the rising threat of antimicrobial resistance. Healthcare professionals can effectively manage infectious diseases and improve patient outcomes by leveraging the available treatment options. In conclusion, anti-infective medicines play a vital role in modern healthcare, allowing healthcare providers to effectively treat and manage bacterial, viral, fungal, and parasitic infections. By employing these treatment options responsibly and in accordance with guidelines, we can mitigate the impact of infectious diseases and ensure better health outcomes for individuals and communities. -Pooja Shah 36| March 2023|www.insightscare.com 38| March 2023|www.insightscare.com Basketball and Physical Fitness any things contribute to a basketball player's Mperformance. A great basketball player has great discipline, is mentally tough, accepts constructive criticism, and is coachable and confident. One of the biggest factors in being a great basketball player is being physically fit. One training tactic to enhance a player's performance is by making practices harder than the game. Players are advised to train twice as hard during practice, so the games become easier to play. Basketball is a physically demanding sport that requires players to repeat intense actions, which is why physical fitness is very important for players. Basketball training requires players to work on different aspects of their bodies to enhance their performance on the court. Since basketball players are constantly in motion on the court, they must build endurance to keep up with the game. Players can work on their endurance by sprinting up and down the court, running miles, or jumping ropes. Running full-court plays and drills is another way to improve endurance. Basketball training also requires players to build muscular strength to execute fundamental movements such as shooting, passing and driving to the basket. Basketball players focus heavily on leg strength since it plays a huge role in shooting a basketball, rebounding, and playing defense. Plyometric training, such as jump squats and single-leg hops, is a great way to enhance leg strength thus improving explosiveness. Basketball training is a great way to promote physical fitness in a fun and social way. What's great about it is training can be done individually or as a team. It can also be done anywhere, not just on a basketball court. Physical fitness is anything that works your muscles and increases your heart/breathing rate, which is what happens in basketball training. It plays an important role in our overall health. For one, physical activity greatly benefits our mental health. Studies have shown that it reduces the risk of anxiety, depression, and stress while improving sleep and concentration. Physical activity also has psychological health benefits, such as improved self-esteem and confidence. More importantly, it enhances a person's quality of life. Physical fitness is known to help maintain a healthy weight by burning excess calories. This can decrease the chances of developing obesity-related diseases. Not only that, it helps reduce the chances of developing a wide variety of chronic diseases. By boosting bone density, a person is less likely to develop bone diseases, like osteoporosis when they get older. It also helps with preventing injuries, especially among athletes. Muscles benefit from physical activity as well. Working our muscles regularly promotes muscle mass or strength. Limited exercise can lead to decreased muscle strength and possibly muscle atrophy. Physical activity is important in combating and preventing chronic heart disease. It helps with maintaining blood pressure, decreases the risk of diabetes, and improves heart health. Wrapping Up It's no secret that there are many benefits to being physically active. It helps with mental, psychological, and physical health. Physical activity isn't limited to gym workouts. Anything that increases heart and breathing rate while promoting muscle movement is considered physical activity. Sports, like basketball, are an exciting way to encourage physical activity among communities. Jordan Meinster is the Founder and CEO of PickUp USA Fitness Franchise Company. Before ge□ng to the health and fitness industry, Jordan worked in hospitality, managing fine dining restaurants, and has a background in finance. Jordan is very health conscious. He especially enjoys maintaining his health through sports like football and basketball. Other ways he stays ac□ e are through hikes and marathons. About the Author 39| March 2023|www.insightscare.com